Korean researchers identify Erbb4 protein as potential Alzheimer's breakthrough

A team of Korean researchers has identified a single protein that may be orchestrating much of the damage in Alzheimer's disease—and blocking it in mice reversed cognitive decline and shrunk toxic brain deposits by more than half. The discovery, published in Nature on Wednesday, points to a potential new strategy for treating a disease that has resisted most existing therapies.

Chung Won-suk and his team at the Institute for Basic Science's Center for Vascular Research found that a protein called Erbb4 acts as a kind of accelerant in Alzheimer's progression. The disease itself is straightforward enough in its hallmarks: memory loss, cognitive decline, and the accumulation of amyloid beta, a sticky protein that clumps in the brain. Scientists have long known that this buildup triggers an overactive immune response that destroys synapses—the connections neurons use to communicate. But drugs that clear amyloid from the brain have proven disappointing. By the time Alzheimer's advances, multiple damaging processes feed into one another, and removing amyloid alone often cannot break the cycle.

The IBS team discovered something unexpected about how that cycle begins. In the early stages of Alzheimer's, glial cells—the brain's housekeeping cells that normally nourish neurons and clear away damage—were stripping away far more synapses from excitatory neurons than from inhibitory ones. Excitatory neurons are the ones that receive signals and form memories. The researchers traced this selective destruction to Erbb4, a protein that normally belongs in inhibitory neurons. In Alzheimer's brains, however, Erbb4 was appearing in abnormally high levels in excitatory neurons, making them hyperactive. The overactive neurons signaled glial cells to remove their connections, which destabilized the brain's neural network and worsened amyloid buildup.

To test whether Erbb4 was truly driving this cascade, the researchers used gene-editing technology to remove it from excitatory neurons in mice with Alzheimer's. The results were striking. The hyperactive neurons stabilized. Synapse damage eased. Brain inflammation subsided. Toxic amyloid deposits shrank by more than 50 percent in both amount and area. The mice performed significantly better on tests of memory and spatial awareness. When the researchers did the opposite—boosting Erbb4 in healthy mice—the animals began showing Alzheimer's-like symptoms. An analysis of brain data from 446 people with Alzheimer's confirmed the pattern: higher Erbb4 levels were associated with more advanced disease and greater cognitive decline.

The findings suggest that Erbb4 is not merely a side effect of Alzheimer's but a key switch that accelerates multiple disease processes simultaneously. Most existing Alzheimer's treatments target individual problems—amyloid buildup here, inflammation there. A drug that blocks Erbb4 could theoretically address several pathways at once. Chung noted that targeting this central link in the disease's cycle could lead to a treatment strategy that addresses the disease's complex pathologies together.

But translating the discovery into a usable drug faces a significant obstacle. Erbb4 is also essential for normal brain function. Blocking it throughout the body could cause serious harm. Kim Dae-soo, a neuroscientist at KAIST, emphasized that researchers would need technology capable of selectively targeting Erbb4 only in the excitatory neurons involved in memory formation. If that precision could be achieved, he suggested, it might be possible to stop dementia in its early stages. The path from laboratory finding to clinic remains long, but the identification of Erbb4 as a central driver of Alzheimer's progression offers a new direction for research that has long struggled to move beyond incremental gains.